| Product | 2.54B |
| Unconsolidated joint business | |
| Other | 98.6M |
| Total revenues | 2.96B |
| Cost of sales, excluding amortization of acquired intangible assets | |
| Research and development | |
| Selling, general and administrative | 462.7M |
| Collaboration profit sharing | |
| Amortization of acquired intangible assets | 99.7M |
| Acquired in-process research and development | |
| Restructuring charge | 11.6M |
| Fair value adjustment of contingent consideration | |
| Total cost and expenses | 1.53B |
| Income from operations | 1.43B |
| Other income (expense), net | |
| Income before income tax expense | 1.37B |
| Income tax expense | 337M |
| Net income | 1.03B |
| Net income attributable to noncontrolling interests, net of tax | -2.7M |
| Net income attributable to Biogen Idec Inc. | 1.03B |
| Basic earnings per share attributable to Biogen Idec Inc. | 4.72 |
| Diluted earnings per share attributable to Biogen Idec Inc. | 4.71 |
| Basic earnings per share attributable to Biogen Idec Inc. | 218.9M |
| Diluted earnings per share attributable to Biogen Idec Inc. | 219.4M |